Visiting a clinical lab, giving a blood sample or a urine cup, and having faith that the organization on the other end of the transaction is acting in your best interests can be subtly unsettling. The majority of people don’t read the fine print. They believe that the test being conducted is the one they truly require. It turns out that this assumption wasn’t always true in the case of Laboratory Corporation of America, or Labcorp.
Two distinct legal settlements involving Labcorp this summer have brought the business under intense public scrutiny. Together, they amount to almost $50 million in agreed-upon payments related to two very different allegations: Medicare billing for medical tests that the government claims were merely unnecessary, and a patient data breach. The scale is important. It is worthwhile to comprehend the specifics.
The majority of former patients may have a stake in the data breach settlement, so let’s start there. A $35 million settlement was reached in a class action lawsuit concerning a seven-month breach related to American Medical Collection Agency, a third-party medical billing company. You may be eligible to submit a claim and receive up to $5,000 if Labcorp provided you with diagnostic services and your personal information was compromised. The deadline for filing claims is September 3, 2026, which is closer than it may seem. The opt-out period ended on July 27th, and the Final Fairness Hearing is set for August 20th in Newark, New Jersey. The time is running out for anyone who hasn’t looked into this yet.
The second settlement tells a different tale. The Department of Justice declared on July 15, 2026, that Labcorp had agreed to pay $14.5 million to settle claims that it had falsified Medicare claims, particularly for urine drug tests that the government considered medically unnecessary. “ToxAssure Comprehensive,” the name of the testing panel at the heart of the case, may sound clinical and comforting, but according to the settlement, it concealed a billing structure that was very profitable for Labcorp.
It’s important to pay attention to its mechanics. Using the same urine sample taken on the same day, Labcorp’s panel combined presumptive and definitive drug tests and billed Medicare for both at the same time. The issue, according to the government, was that Labcorp completely omitted the presumptive test for a number of substances and proceeded directly to the more costly definitive test without first determining whether the additional testing was clinically necessary. In order to avoid needless layering of charges, Medicare, for its part, has bundled payment rules. Despite this, Labcorp billed both the highest-tier codes.
It’s noteworthy that Labcorp didn’t simply fight and deny everything. The fundamental facts specified in the agreement were acknowledged, accepted, and acknowledged by the company. Additionally, it has already ceased using the ToxAssure Comprehensive combination of codes to bill Medicare. According to Justice Department guidelines, they received credit for their level of cooperation, which may explain why the $14.5 million figure isn’t higher. However, it represents a real pattern of behavior over almost six years, from January 2018 to late 2023, and it is still real money.
Beneath all of this is a more general question. Labcorp is a large, local company. With hundreds of millions of tests processed annually, it is one of the biggest clinical laboratory networks in the nation. It begs the question of whether the problem was a rogue department or something more structural when a company of that size creates a billing panel that routinely charges for more than patients probably need. As these agreements frequently do, the settlement leaves that question unanswered.
It’s important to note that these two lawsuits are running concurrently with other ones against Labcorp. A different $9 million class action settlement pertaining to a Washington state case was settled in May 2025. The accessibility of Labcorp’s self-check-in kiosks for blind patients is the subject of another ongoing case that has reached the federal appellate level and touches on disability rights in a way that extends far beyond Labcorp.
